

Ramucirumab RAISE

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

OS

ADJUSTMENTS

Quality of life

No QoL benefit

Serious and disabling adverse effects

Other adjustments

Ramucirumab RAISE

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

1

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Treatment of patients with mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine

Experimental Arm: Ramucirumab + FOLFIRI (folinic acid, 5-fluorouracil, irinotecan)

Control Arm: FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) + placebo

